The product, currently designated as FYB206, represents the first publicly announced FDA application for a Keytruda biosimilar. Under the existing licensing agreement, the acceptance of this filing mandates an undisclosed milestone payment from Zydus to Formycon. Zydus maintains exclusive commercialization rights for the drug in the United States and Canada, with a final regulatory verdict anticipated by the third quarter of 2027.

While several pharmaceutical firms are racing to develop competing versions of the blockbuster treatment, the first to secure market entry stands to gain a substantial economic advantage before pricing pressures intensify. For Formycon, the recent market reaction helps recover some ground after a 14% decline in its share value earlier this year.